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ABSTRACT  
Cyclodextrins (CDs) are a family  of compounds consist of  glucose  monomers arranged in a donut  shape ring. They are non-reducing,  crystalline cyclic 
oligosaccharides  which  proximate  a  truncated  core  generating  a  hydrophilic  outer  surface  and  a  lipophilic  interior  cavity  that  offers  interaction  with 
appropriately  sized  molecules  to  result  in  the  formation  of  inclusion  complex.  Cyclodextrins  are  able  to  form  host-guest  complexes  with  hydrophobic 
molecules given the unique nature imparted by their structure. As a result, these molecules have found a number of applications in a wide range of fields. The 
proposed review explores the various techniques used and advantages for the formation of inclusion complex. The CDs have a wide range of applications in 
different areas of drug delivery and pharmaceutical industry due to their use as complexing agent to increase the aqueous solubility of poor soluble drugs and 
to increase their bioavailability and stability. The article also highlights extensive use of CDs as a polymer in the design of various novel delivery systems like 
liposomes,  microspheres,  nanoparticles  that  can  be  expected  to  improve  the  therapeutic  efficacy  of  drug  and  patient  compliance.  The  objective  of  this 
contribution is to point out the inherent use of chemically modified cyclodextrins as high performance drug carriers in drug delivery systems with emphasis on 
the current  developments. Thus, CDs  because of  their continuing ability to  find  several novel applications in  drug delivery are  expected to  solve  many 
problems associated with the delivery of different novel drugs through different delivery routes. 
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INTRODUCTION 
CDs  are  cup-shaped  molecular  cages  composed  of  cyclic 
oligosaccharides.  They  are  novel  excipients  having 
glucopyranose units that exhibit amphoteric properties of  a 
lipophilic central cavity and a hydrophilic outer surface
1. CDs 
are homologous group of cyclic glucans consisting of α-1, 4 
bound  glucose  units.  They  are  obtained  by  the  action  of 
cyclodextrin  glucanotransferase  (CGTase)  on  starch  or 
similar  substrates  to  produce  a  mixture  of  cyclodextrins 
comprised  of  6,  7  and  8  glucose  units  (α,  β,  and  γ-
cyclodextrin, respectively). Commercially, cyclodextrins are 
still produced from starch, but specific enzymes are used to 
selectively produce consistently pure α, β and γ-cyclodextrin, 
as  desired
2.  The  hydrophilicity  of  the  outer  surface  of  the 
CDs  is  due  to  the  presence  of  hydroxyl  groups  while 
hydrophobic inner cavity is seamed with skeletal carbons and 
ethereal  oxygen  thus  rendering  a  microenvironment  for 
appropriately sized non-polar moiety acting as a guest
3. The 
group  of  forces,  including  Vander  Waals,  hydrogen  bonds 
and  hydrophobic  effects  contribute  to  the  formation  of  a 
stable complex of drugs in the apolar cavity of cyclodextrins. 
Cyclodextrins possess a cage-like supramolecular structure, 
similar to the structures formed from spherands, cryptands, 
calixarenes, cyclophanes, and crown ethers, thus are having 
truncated  cone  or  torus  shape  rather  than  being  a  perfect 
cylinder
4.  As a result of their molecular structure and shape, 
cyclodextrins  possess  a  unparalleled  ability  to  act  as 
complexing  ligands  capable  of  hosting  a  large  variety  of 
guest molecules to form non-covalent inclusion complexes
5. 
Such  type  of  hosting  can  camouflage  many  non-desirable 
physicochemical characteristics of the various guest moiety 
and helps in enhancing their aqueous solubility, dissolution, 
stability  and  bioavailability,  thus  evidencing  CDs  to  be 
greatly  relevant  in  the  pharmaceutical,  agrochemical,  food 
and cosmetic industry
6.  
(Figure 1) 
Advantages 
1.  CDs  help  in  improving  the  aqueous  solubility  of  many 
poorly soluble drugs. 
2.  CDs  enhances  the  dissolution  thus  helps  in  enhancing 
bioavailability of drugs.  
3.  CDs  complexation  improves  the  chemical,  physical  and 
thermal stability of drugs. 
4.  CDs  inclusion  complexation  helps  in  ameliorating  the 
irritancy of the drug moiety that   irritates the stomach, skin 
or eye.  
5. CDs cloak the unpleasant odour and bitter taste of drugs. 
6.  Complexing  oily  or  sticky  substances  with  CDs  into 
microcrystalline or amorphous   powders help in improving 
the material handling properties. 
7. Formulation of modified release preparations. 
8. CDs helps in decreasing the toxic effects associated with 
drugs. 
9.  CDs  have  also  been  used  in  the  novel  pharmaceutical 
applications. 
TYPES OF CYCLODEXTRINS 
More  than  1500  CD  derivatives  have  been  reported  in  the 
literatures. However, the most common parent cyclodextrins 
are α-, β- and γ-CDs containing 6, 7 and 8 glucopyranose 
units respectively. Chemically, they are torus-like macro-ring 
oligosaccharides  containing at least  6  D-(+)  glucopyranose 
units attached by α-(1, 4) glucosidic  bonds. CDs with less 
than  6  units  cannot  be  formed  due  to  stearic  hindrance 
problems.  These  parent  CDs  are  natural,  non-reducing, 
crystalline,  homogeneous,  non  hygroscopic  having  limited 
aqueous  solubility  due  to  strong  intermolecular  hydrogen 
bonding  in  the  crystal  lattice
7.  However,  these  parent 
cyclodextrins are also associated with many limitations and 
to  extend  their  physicochemical  properties  and  inclusion 
capacity,  the  chemically  modified  derivatives  of  these 
parental CDs have been prepared which are amorphous, non 
crystallisable with enhanced aqueous solubility, physical and 
microbiological  stability,  and  reduced  parenteral  toxicity
8.
 
The  various  derivatives  that  have  gained  pharmaceutical 
interest include: 
·  Natural CDs: α-, β- and γ-CDs 
·  Hydroxyalkylated CDs: HPβCD and HPγCD 
·  Methylated CDs: RAMEB (randomly methylated βCD) Ali Nasir et al. IRJP 2012, 3 (4) 
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·  Acetylated CDs: Acetyl γCD 
·  SBEβCD (Sulfo butyl ether β-cyclodextrin)  
·  Branched CDs: maltosyl and glucosyl βCD 
·  Reactive CDs: chlorotriazinyl βCD (Table 1) 
APPROACHES  FOR  MAKING  INCLUSION 
COMPLEXES 
Physical  Blending  Method:  The  method  involves 
homogenous blending of the physical mixture of drug and CD 
followed by passing the mixture through an appropriate sieve 
to get the desired product.  
Kneading Method: In this method, drug and CD are grinded 
with intense trituration for approx. 30 min. The mixture is then 
kneaded  with  hydroalcoholic  solution  to  get  a  pasty 
consistency. The mass is then dried at 40°C for 1 hour, stored 
overnight  in  vacuum desiccators  and  passed  through no. 80 
sieve to get the desired product
9. 
Solvent  Evaporation  Method:  Also  known  as  solid 
dispersion method, involves mixing of the alcoholic solution 
of  drug  and  aqueous  solution  of  CDs  with  stirring to  get  a 
molecular dispersion, followed by evaporation of the solvent 
under vacuum until dried mass is obtained. The dried mass is 
then pulverized and sieved to get the complexed product
10. 
Spray Drying Method: Also known as atomization method, 
a  common  technique  involving  preparation  of  monophasic 
solution  of  drug  and  cyclodextrin  using  a  suitable  solvent 
system  generally  in  ethanol:  water  50%  v/v.  The resulting 
mixture is then stirred for 24 hr. at room temperature to attain 
equilibrium following which the solvent is removed by spray 
drying. The sufficient and effective interaction between the 
drug and CDs to form a perfect complex is the plus advantage 
of this technique
11. 
Freeze  Drying  Technique:  Also  known  as  lyophillisation 
technique suitable to get a porous, amorphous powder. In this 
technique,  stoichiometric  amount  of  drug  and  CDs  are 
dispersed in hydro alcoholic solution using a magnetic stirrer. 
After agitating for a specific time, the resulting solution is 
frozen  and  lyophilised  under  reduced  pressure  in  a  freeze 
dryer. This technique is suitable for thermolabile substances 
as they can be successfully made into complex form
12.   
Microwave  Irradiation  Technique:  This  method  involves 
the  microwave  irradiation  reaction  between  drug  and 
complexing agent using a microwave oven. This is a novel 
method  for  industrial  scale  preparation  which  requires  a 
shorter reaction time and higher aim product
13. 
Melting:  This  method  involves  melting  excess  amount  of 
guest followed by mixing with powdered CD. The drug-CD 
mixture  is  cooled  and  the  excess  amount  of  guest  is  then 
removed by carefully washing with weak complex forming 
solvent or by sublimation under vaccum
14. 
Supercritical  Antisolvent  Technique:  In  this  technique, 
carbon dioxide is used as antisolvent for the solute but act as 
a solvent with respect to the organic solvent. Drug and CD 
are dissolved in a suitable solvent followed by  feeding the 
solution through a nozzle into a pressure vessel containing 
supercritical fluid anti-solvent. When the solution is sprayed, 
the anti-solvent rapidly diffuses into that liquid solvent as the 
carrier liquid solvent counter diffuses into the anti-solvent. 
Because of the supercritical fluid expanded, solvent has lower 
solvent  power  than  the  pure  solvent,  the  mixture  becomes 
supersaturated resulting in the precipitation of the solute and 
the solvent is carried away with the supercritical fluid flow. 
This is a non toxic and fast process
 15. 
High Pressure Homogenization Method: In this technique, 
drug and CD in an appropriate solvent are mixed together and 
the passed through a high-pressure homogenizer causing the 
disintegration  of  particles  and  dispersion  throughout  the 
product. The eventual solution was filtered and evaporated to 
dryness until the solid complex was acquired
16. 
CYCLODEXTRINS  APPLICATION  IN  DRUG 
DELIVERY SYSTEMS 
Cyclodextrins  are  able  to  form  host-guest  complexes  with 
hydrophobic molecules given the unique nature imparted by 
their  structure.  As  a  result  of  this  multifunctional 
characteristic  of  CDs,  enabling them  to  be  used  in  almost 
every drug delivery system, be it oral drug delivery or ocular 
drug delivery or in novel drug delivery systems. An update 
on the recent work done in different fields is presented below. 
Cyclodextrins in Oral Drug Delivery 
Nearly  40%  of  the  new  chemical  entities  currently  being 
discovered are poorly water soluble drugs, thus to enhance 
their efficacy is a challenging task in drug development. The 
most common pharmaceutical application of CDs in oral drug 
delivery  includes  enhanced  drug  solubility  in  aqueous 
solutions  thus  resulting  in  an  enhanced  dissolution  and 
bioavailability, and stability of the drug at the absorption site 
or in formulation, reduction of drug induced irritation, and 
taste making. Beside this, CDs are potential candidates for 
modified release carriers as chemically modified CDs may 
serve as novel slow release carriers for water soluble drugs 
including  proteins  and  peptides.  Cyproheptadine 
hydrochloride  is  a  poorly  soluble  antihistaminic  drug, thus 
motives adjustment to heighten the efficacy. The solubility of 
the drug was successfully bumped to 9.69mg/ml at pH 6.8 
with β-CD inclusion complex by preparing solid dispersion 
as compared to 2.09mg/ml of that of pure drug. Thus CDs 
role in enhancing drug solubilisation was found crucial
17. The 
use  of  Cyclosporine  A  for  inhalation  therapy  of  asthma  is 
limited  by  its  hydrophobic  properties.  However,  complex 
formation with maltosyl α-CD not only reduced the effective 
drug dose but wider therapeutic safety margin on inhalation 
of  Cyclosporine  A  was  also  expected
18.  Complexation  of 
Repaglinide,  an  antidiabetic  drug,  with  HPβCD  using 
lyophillisation technique showed an enhanced solubility thus 
improving dissolution profile of the drug also
19. Bitter taste 
and odour of drugs can also be masked by forming inclusion 
complex  of  drug  and  CDs  thus  making  the  drug  to  be 
acceptable orally. e.g. βCD has potential of masking the bitter 
taste of drug like Oseltamivir Phosphate (OP). In addition, 
prepared FDC exhibited better drug release at pH 1.2 and less 
at pH 6.8.  The results of TPS indicate effective taste masking 
as  compared  to  pure  drug.  In  conclusion,  the  study 
corroborated  that  CD  can  be  utilized  as  an  alternative 
approach for effective taste masking of OP
20. NSAIDS, like 
Piroxicam,  Indomethacin  showed  side  effects  like  gastric 
ulceration.  However,  it  was  found  that  complexing  these 
NSAIDS with β-CD and HPβCD ameliorate the induction of 
gastric ulcers induced by restraint and cold stress in rats
21. 
Oral  antifungals  like,  Itraconazole,  Saperconazole  showed 
greatly enhanced bioavailability with HPβCD complexation. 
The  wide  variety  of  CDs  available  has  made  possible  to 
modify the drug release and thus providing option for drug to 
be  released  either  immediately,  or  sustainly.  Molecular 
complex of glipizide with β-CD play a vital role to obtain a 
uniform,  controlled  and  complete  drug release  of  a  poorly 
soluble drug from the swellable /erodible matrix tablet. Thus, 
CD  can  be  applicable  in  formulating  sustained  release 
formulations  also
22.  Very  limited  aqueous  solubility  and 
wettability of Vinpocetine (VP) give rise to problems of both 
formulation  and  bioavailability.  However,  VP-CD-Tartaric Ali Nasir et al. IRJP 2012, 3 (4) 
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acid  multi-component  complexes  when  prepared  and 
formulated in HPMC matrix tablets showed  controlled and 
almost complete release behavior of drug over a 12hr period 
when  compared  to  vinpocetine  immediate  release  dosage 
form.  Thus,  CD-VP  complexation  improves  oral 
bioavailability  of  drug  and  controlled  release  delivery 
strategies
23. (Table 2) 
Cyclodextrins in Ophthalmic Drug Delivery 
Various drug formulations in the form of suspensions, eye 
drops,  ointments,  gels  and  solid  inserts  are  available  for 
topical  administration  into  the  eye.  But  most  of  these 
formulations are associated with unwanted side effects like 
eye  irritation,  blurred  vision  and  discomfort.  Also  drug 
solubility, stability criteria have also to be considered while 
formulating drugs for ocular delivery. CDs, especially 2HP- 
β-CD  and  SBE-β-CD  are  shown  to  be  well  tolerated  in 
aqueous  formulations  and  are  non  toxic  to  the  eye,  thus 
proving  to  be  beneficial  excipients  for  ocular  formulation. 
Eye drops are also associated with the limitability to sustain 
high concentration of drugs. However, incorporating ocular 
drugs  into  gels  or  polymer  matrix  have  been  shown  to 
increase  the  contact  time.  Benefits  of  using CDs  in  ocular 
formulations include: 
i.  Provides sustained release of drug. 
ii.  Enhancing  solubilisation  and  chemical  stabilization  of 
drug. 
iii.  Enhancement of ocular drug permeability. 
iv.  Reduced ophthalmic drug irritation and discomfort. 
Formulation  with  HP-β-CD,  with  and  without  HPMC, 
improved the bioavailability and maximal mydriatic response 
of tropicamide by enhancing the drug’s ocular permeability, 
but  reduced  the  ocular  drug  irritation  probably  by 
maintaining  the  pH  in  physiologic  range.  Gancyclovir,  an 
acyl  ester  prodrug  upon  complexing  with 5%  w/v  HPβCD 
showed  an  improved  stability  and  corneal  permeation  by 
solubilising  the  hydrophobic  prodrug  to  2.5  folds  and 
delivering it across the mucin layer at the corneal surface
38
. A 
formulation  consisting  of  drug  zinc-diethyldithiocarbamate 
with  HP-β-CD  complexation  was  prepared  along  with 
addition of polymers and penetration enhancers and this drug 
delivery system increases both the drug solubility in aqueous 
eye  drops  and  the  permeability  of  drug  through  the rabbit 
cornea
39.
  An  aqueous  ocular  delivery  system  for  the  poor 
water  soluble  anti-inflammatory  drug  Indomethacin  was 
prepared using HP-β-CD as a complexing agent. Besides a 
sufficient solubility for the drug, many factors were examined 
in  the  development  of  this  system,  such  as  stability  and 
safety.  Formulated  Indomethacin-HP-β-CD  eye  drops 
exhibited delayed release and high drug stability compared to 
the  drug  solution.  In  addition,  Indomethacin-HP-β-CD  eye 
drops  showed  promising  management  to  corneal 
inflammation
40. Norfloxacin is a poorly water soluble drug, 
was  complexed  with  β-cyclodextrin.  Several  ocular 
patches/inserts  of  Norfloxacin-β-CD  were  prepared  in 
hydroxypropyl  methyl  cellulose  (HPMC)  matrix.  The 
influence  of  rate  controlling  membranes  made  of  ethyl 
cellulose  (EC)  alone  and  in  combination  with  polyvinyl 
pyrrolidone  K30  (PVP  K30)  on  drug  release  kinetics  was 
studied.  The  study  confirmed  the  improved  solubility  of 
Norfloxacin when complexed with β-cyclodextrin and that it 
can be delivered through films made of HPMC matrix cast 
with EC alone or with a combination of PVPK30
41. (Table 3) 
Cyclodextrins in Transdermal Drug Delivery 
The topical availability of drugs depends on the criteria that 
the drug should be able to dissolve in the vehicle (base), and 
should permeate the skin barrier to show the effect. However, 
most of the drugs fail to meet this unique amphiphillic nature 
requirement.  Hence,  formulations  require  incorporation  of 
excipients  like  permeation  enhancers,  solubilizers  etc.  that 
can overcome the problems of either or both of the transport 
processes (i.e. dissolution into vehicle and diffusion across 
skin). The main limitation of this route is to overcome the 
stratum  corneum,  the  outermost  skin  barrier.  In  order  to 
achieve therapeutic concentrations and to improve the drug 
flux,  permeation  enhancers  are  used  to  optimize  drug 
permeation through the skin. Besides the potential of CDs in 
enhancing  the  solubility,  they  can  be  used  as  membrane 
permeability enhancer and stabiliser
50. CDs have been used 
as permeation enhancers although their mechanism is not yet 
well known. CDs play an important role in optimizing local 
and systemic dermal drug delivery. Benefits of using CDs in 
transdermal drug delivery include: 
i.  Enhancement of drug release and/or permeation. 
ii.  Stabilisation of drug in the formulation or at absorptive 
site. 
iii. 
 Enhanced solubilisation of lipophilic drug. 
iv.  Alleviation of drug induced local irritation. 
v.  Providing sustained release of drug from vehicle. 
vi.  Alteration of drug bioconversion in the viable skin. 
Piroxicam  formed  an  inclusion  complex  with  β-CD  and 
RAMEB  that  additionally  improved  the  drug  dissolution 
properties. Incorporation of the drug β-CD inclusion complex 
in hydrophilic gel effectively enhanced the drug permeation 
across  semi  permeable  membrane
51.    Drugs  must  retain 
sufficient stability, not only during storage but also at the site 
of application. Various studies report CD as a drug stabilizer 
in  dermal  drug  delivery.  Complex  of  dermatocorticoid, 
tixoxortol-17-butyrate-21-propionate, with β-CD included in 
vaseline  and  o/w  emulsion  showed  stability  after  30  days 
storage  at  40°C.  Oral  therapy  with  glipizide  comprises 
problems  of  bioavailability  fluctuations  and  may  be 
associated  with  severe  hypoglycemia  and  gastric 
disturbances. As a potential for convenient, safe and effective 
antidiabetic  therapy,  transdermal  delivery  system  was 
developed. For this purpose, inclusion complexes of the drug 
in various CDs were prepared. Release studies revealed an 
improved release of the drug from formulations containing 
glipizide-CD complexes
52. Recently, CDs in dermal delivery 
of  proteins  and  peptides  has  been  noted.  For  example,  a 
combination  of  β-CD  and  the  permeation  enhancer  Azone 
achieved higher percutaneous absorption of a peptide drug, 
nafarelin  acetate,  and  a  luteinizing  hormone  releasing 
analog
53. (Table 4) 
Cyclodextrins in Nasal Drug Delivery 
Highly  potent  drugs  can  be  aimed  for  systemic  delivery 
through nasal mucosa. This novel approach is beneficial for 
the  drugs  with  a  low  oral  bioavailability  due  to  extensive 
gastro-intestinal breakdown and high hepatic first-pass effect. 
For lipophilic drugs nasal delivery is possible if they can be 
dissolved in the dosage form. CDs are safe and non toxic, 
thus are effective excipients for nasal drug delivery as they 
can enhance either drug absorption by increasing the aqueous 
solubility  or  by  enhancing  drug  permeability  or  both.  The 
hydrophilic  CDs  enhance  membrane  permeability  by 
solubilising some specific lipids from biological membrane 
through  the  rapid  and  reversible  formation  of  inclusion 
complexes. Beside this, they can decrease the nasal toxicity 
and can act as a carrier for sustained release of drug across 
nasal  mucosa.  HP-β-CD  and  methylated  β-CDs  have  been 
used mainly as solubilizers and absorption enhancers in nasal Ali Nasir et al. IRJP 2012, 3 (4) 
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drug delivery system. Administration of lipophilic drugs such 
as female steroid hormones Estradiol
60 and progesterone with 
CDs  has  shown  rapid  absorption.  Progesterone,  a  poorly 
water  soluble  drug  possess  complications  in  oral  delivery 
because  of  high  first  pass  metabolism,  thus  results  in  a 
limited oral efficacy. Formulations of progesterone as gels for 
nasal  administration  with  carbopol  containing  β-CD  and 
HPβCD  as  solubilizers  and  absorption  enhancers  were 
prepared. In vivo studies in rabbits for nasal absorption of 
progesterone  show  a  rapid  increase  in  plasma  levels  and 
promising  bioavailability  values
61.  Interaction  of  the 
antipsychotic  drug  Risperidone  with  HPβCD  was  studied 
with the aim of overcoming the limitations associated with 
nasal  administration  of  low  solubility  drugs.  The  in  vitro 
dissolution  studies  showed  that  formation  of  the  inclusion 
complex  significantly  increased  the  risperidone  dissolution 
rate from the micro particles, thus providing sustained drug 
release
62. The use of methylated cyclodextrin derivatives in 
formulations for enhancing the nasal bioavailability of insulin 
in rats from about 0-100% was observed
63.  (Table 5) 
Cyclodextrins in Liposomal Drug Delivery 
The  main  motive  of  the  liposomal  drug  delivery  is  to 
combine  the  advantages  of  CDs  such  as  increased  drug 
solubility  with  the  advantages  of  liposome  such  as  drug 
targeting. A novel concept in drug delivery takes advantage 
of certain properties of the drug "containers" cyclodextrins 
and  liposomes  to  combine  them  into  a  single  system  thus 
circumventing  problems  associated  with  both  systems.  The 
concept, entailing entrapment of water-soluble cyclodextrin-
drug  inclusion  complexes  in  liposomes,  would  allow 
accommodation of insoluble drugs in the aqueous phase of 
vesicles
.  A  combined  strategy,  based  on  cyclodextrin 
complexation and loading in liposomes, has been investigated 
to develop a new delivery system with improved therapeutic 
activity  of  the  local  anesthetic,  prilocaine  (PRL). 
Cyclodextrin  complexation  not  only  allowed  an  efficient 
encapsulation of PRL base in the aqueous vesicle core, but 
also increased the anesthetic effect duration and reduced the 
initial  lag  time,  in  comparison  with  the  corresponding 
formulations  containing,  respectively,  free  PRL  in  the 
lipophilic phase or PRL hydrochloride in the aqueous vesicle 
core
67.  Curcumin  is  water  insoluble  drug  and  an  effective 
delivery  route  is  through  encapsulation  in  cyclodextrins 
followed by a second encapsulation in liposomes. Curcumin-
loaded γ-cyclodextrin liposomes indicate significant potential 
as delivery vehicles for the treatment of cancers of different 
tissue origin
68. Conventional drug-loading technologies have 
typically resulted in undesired drug retention properties. To 
resolve the problem, a modified gradient loading method was 
developed for irinotecan encapsulation. The novel SBE-CD 
gradient  could  mediate  effective  irinotecan  loading  and 
improve irinotecan retention, thus resulting in highly active 
liposomal irinotecan formulations
69. (Table 6) 
Cyclodextrins in Microspheres 
CDs can be used extensively as a polymer in microspheres 
that can be expected to improve the therapeutic efficacy of 
drug  and  patient  compliance.  The  potential  of  CDs  to 
stabilize α-chymotrypsin upon encapsulation in Poly (lactic-
co-glycolic) acid (PLGA) microspheres using a solid-in-oil-
in-water  (s/o/w)  technique  was  investigated.  The  results 
suggest that MβCD can be a suitable excipient to improve 
protein stability in s/o/w encapsulation procedures
73. HP-β-
CD acted as a promising agent for stabilizing lysozyme and 
bovine serum albumin during primary emulsification of poly 
(d, l-lactide-co-glycolide) (PLGA) microsphere preparation. 
The stabilizing effect was reported to be a result of increased 
hydrophilicity  of  the  proteins  caused  by  shielding  of  their 
hydrophobic  residues  by  HP-β-CD
74.  Sustained  release 
chitosan/β-cyclodextrin  microspheres  of  theophylline  were 
prepared  by  spray  drying  method.  The  effect  of  several 
formulation variables on the characteristics of microspheres 
was studied. The microspheres showed a prolonged release 
pattern with the release rate of 60.20% (pH 6.8) within 8 h
75. 
(Table 7) 
Cyclodextrins in Nanoparticles   
The safety and efficacy of nanoparticles are limited because 
of  their  very  low  drug  loading  and  limited  entrapment 
efficiency.  CDs  played  an  important  role  in  designing 
nanoparticles  by  enhancing  drug  loading  capacity  and  the 
spontaneous formation of either nanocapsules or nanospheres 
of amphiphilic CDs diester’s nanoprecipitation. Thus, opted 
suitable to provide targeted drug delivery and to enhance the 
efficacy  and  bioavailability  of  poorly  soluble  drugs. 
Paclitaxel  is  a  potent  anticancer  agent  with  limited 
bioavailability due to side-effects associated with solubilizers 
used and the tendency of the drug to precipitate in aqueous 
media.  Amphiphilic  cyclodextrin  nanoparticles  emerged  as 
promising  alternative  formulations  for  injectable  paclitaxel 
administration  with  low  toxicity  and  equivalent  efficacy. 
Hydroxyapatite (HA) containing levels of β-CD of upto 0.9 
wt%  has  been  produced  by  co-precipitation  method.  The 
results show that an increase in concentration of β-CD in the 
prepared samples that leads to an increase in hydrophobicity 
seems  to  promote  an  affinity  for  albumin  adsorption.  The 
results  indicate  that  HA/β-CD  complexes  have  immense 
potential in targeted delivery of drugs
76. Captopril (CAP) was 
the first angiotensin I-converting enzyme (ACE) inhibitor to 
be developed and is widely used in hypertension treatment. 
The nanoparticles obtained by the kneading method (CAP/α-
CD: KM) showed a potent and long-lasting inhibitory activity 
(~22 hours) on the angiotensin I pressor effect. The results 
suggest  that  the  inclusion  complex  of  CAP  and  α-CD  can 
function  as  a  novel  antihypertensive  formulation  that  may 
improve  therapeutic  use  of  CAP  by  reducing  its  oral 
administration to once a day
77. (Table 8) 
CONCLUSION 
The  proposed  review  on  Cyclodextrins  (CDs)  explores  its 
utility  as  useful  functional  excipients  that  have  enjoyed 
widespread attention and use in the pharmaceutical industry. 
The  bioadaptability  and  multi-functional  characteristic  of 
CDs  make  them  capable  of  alleviating  the  undesirable 
properties  of  drug  molecules  in  various  routes  of 
administration through the formation of inclusion complexes. 
CDs,  as  a  result  of  their  complexation  ability  and  other 
versatile  characteristic  are  continuing  to  have  different 
applications in different areas of drug delivery, thus proving 
CDs  to  be  greatly  applicable  in  the  pharmaceutical, 
agrochemical,  food  and  cosmetic  industry.    CDs  use  as  a 
polymer  in  NDDS  like  liposomes,  nanoparticles  and 
microspheres is expected to improve the therapeutic efficacy 
of  drug  and  patient  compliance.  In  future,  CDs may  solve 
various  problems  associated  with  drug  delivery  through 
complexation. 
REFERENCES 
1. Szejtli J. Cyclodextrin Technology. Dordrecht (The Netherlands): Kluwer 
Academic Publishers; 1988; 81-83. 
2.  Biwer  A,  Antranikian  G,  Heinzle  E.  Enzymatic  production  of 
cyclodextrins. Appl Microbiol Biotechnol 2002; 59(6): 609–17. 
3. Vogtle F.  Supramolecular Chemistry: An Introduction. New York: John 
Wiley and Sons Ltd 1991; 135.  Ali Nasir et al. IRJP 2012, 3 (4) 
Page 48 
4. Laza-Knoerr AL, Gref R, Couvreur P. Cyclodextrins for drug delivery. J 
Drug Target 2010; 18(9): 645-56. 
5.  Loftsson  T,  Brewster  M.  Pharmaceutical  applications  of  cyclodextrins; 
Drug solubilization and stabilization. J Pharm Sci 1996; 85: 1017-1025. 
6. Rajewski RA, Stella VJ. Pharmaceutical applications of cyclodextrins. ii. 
in vivo drug Delivery. J Pharm Sci 1996; 85:1142-69. 
7.  Hakkarainen  B,  Fujita  K,  Immel  S,  Kenne  L,  Sandstrom  C. 
1H  NMR 
studies on the hydrogen-bonding network in mono-altro-β-cyclodextrin and 
its complex with adamantane-1-carboxylic acid. Carbohydr Res 2005; 340: 
1539–1545. 
8. Szente L, Szejtli J. Highly  soluble  cyclodextrin  derivatives: Chemistry, 
properties, and trends in development.  Adv Drug Deliv Rev 1999; 36:17-38. 
9. Reddy  MN, Rehana
 T,
 Ramakrishna S, Chowdary  KPR, Diwan  PV. β-
Cyclodextrin  Complexes  of  Celecoxib:  Molecular-Modeling, 
Characterization,  and  Dissolution  Studies.    AAPS  Pharm  Sci  Tech  2004; 
6(1): 1-9. 
10.  Pravin  A,  Nagarsenker  MS.  Triamterene-β-CD  system;  preparation, 
characterization and in vivo evaluation.  AAPS Pharm Sci Tec 2004; 5(1): 1-
8. 
11. Sanjula B, Mona D, Kanchan K. Physicochemical characterization, in-
vitro  dissolution  behavior,  and  pharmacodynamic  studies  of  rofecoxib-
cyclodextrin inclusion compounds.  AAPS Pharm Sci Tech 2005; 6(1): 14. 
12.  Moyano  JR,  Gines  JM,  Arias  MJ,  Rabasco  AS.  Study  of  dissolution 
characteristics  of  oxazepam  via  complexation  with  β-cyclodextrin.  Int  J 
Pharm 1995; 114: 95-102.  
13. Xianu HW, Fei T, Zhijun J. Preparation and study of the 1:2 inclusion 
complex of carvedilol with β-cyclodextrin.  J Pharm Biomed Anal 2004; 34: 
517-523.  
14. Marie W, Maggie A. Solid state studies of drug-cyclodextrin inclusion 
complexes in PEG-6000 prepared by new method.  Eur J Pharm Sci 1999; 8: 
269-281. .  
15.  Vamsi  KM,  Gowrisankar  D.  Role  of  Supercritical  fluids  in  the 
Pharmaceutical Research-A Review. Indian J Pharm Edu Res 2007; 41(1): 
10-17. 
16. Liu HK, Lo YK, Tsai TR, Cham TM.  Physicochemical characterizations 
of  Osthole  hydroxypropyl-β-cyclodextrin  inclusion  complexes  with  High-
Pressure Homogenization Method. Journal of Food and Drug Analysis 2010; 
18(6): 391-397. 
17. Gupta AK, Sehrawat S, Kumar A, Mishra DN. Solubility enhancement of 
cyproheptadine by formulating inclusion complexes. International Journal of 
Pharmaceutical Sciences Review and Research 2011; 9(1): 132-135.   
18. Fukaya H, Iimura A, Hoshiko K, Fuyumuro T, Noji S, Nabeshima T. A 
cyclosporin  A/maltosyl‐α‐cyclodextrin  complex  for  inhalation  therapy  of 
asthma. European Respiratory Journal 2003; 22(2): 213-219. 
19. Nicolescu C, Arama C, Nedelcu A,  Monciu CM. Phase solubility studies 
of  the  inclusion  complexes  of  Repaglinide  with  β-Cyclodextrin  and  β-
Cyclodextrin derivatives. Farmacia 2010; 58(5): 620-28. 
20.  Sevukarajan  M,  Thanuja  B,  Nair  R.  Novel  Inclusion  Complexes  of 
Oseltamivir  Phosphate-with  ß  Cyclodextrin:  Physico-Chemical 
Characterization. J. Pharm. Sci. & Res 2010; 2(9): 583-589. 
21. Alsarra IA, Ahmed MO, Alanazi FK, Tahir KEH, Alsheikh AM, Neau 
SH. Influence of Cyclodextrin Complexation with NSAIDs on NSAID/Cold 
Stress-Induced Gastric Ulceration in Rats. 
 Int J Med Sci 2010; 7: 232-239. 
22. Bhosale AV, Hardikar SR, Jagtap RS, Patil NB, Dhawale SS, Shirsath 
SC. Formulation  of beta cyclodextrin complexed controlled release matrix 
tablet of glipizide and its in-vitro evaluation. Int. J. PharmTech 2009; 1(3): 
773-778. 
23. Ribeiro et al. Cyclodextrin multicomponent complexation and controlled 
release delivery strategies to optimize the oral bioavailability of vinpocetine. 
J Pharm Sci 2007; 96(8): 2018-28. 
24.  Petralito  S,  Zanardi  I,  Memoli  A,  Annesini  MC,  Travagli  V. 
Cyclodextrin/Diacerein  inclusion  complex:  A  tool  for  therapeutic  drug 
delivery. Chemical Engineering Transactions 2011; 24: 967-972. 
25.  Singh  I,  Kumar  P,  Pahuja  S,  Tung  V,  Arora  S.  Development  and 
pharmacological evaluation of cyclodextrin complexes of etoricoxib.  Acta 
Poloniae Pharmaceutica and Drug Research 2011; 68(2): 279-284. 
26.  Domanska  U,  Pelczarska  A,  Pobudkowska  A.  Effect  of  2-
Hydroxypropyl-β-cyclodextrin  on  solubility  of  sparingly  soluble  drug 
derivatives of Anthranilic Acid.  Int. J. Mol. Sci 2011; 12: 2383-2394. 
27.  Kumar  GV,  Murthy  TEGK.  In-Vivo  Evaluation  of  Carvedilol-Β-
Cyclodextrin Inclusion Complexes. International Journal of Pharmaceutical 
& Biological Archives 2011; 2(3): 954-957. 
28.  Ghosh  A,   Biswas  S,   Ghosh  T.  Preparation  and  evaluation  of 
silymarin β-cyclodextrin molecular inclusion  complexes. Journal of Young 
Pharmacists 2011; 3(3): 205-210. 
29.  Dua K,  Pabreja K,  Ramana MV,
   Lather V. Dissolution behavior of β-
cyclodextrin  molecular  inclusion  complexes  of  aceclofenac.    Journal  of 
Pharmacy and Bioallied Science 2011; 3(3): 417-425. 
30. Patel VP, Gohel MC, Parik RK. In Vitro Dissolution Enhancement of 
Felodipine. Indo-Global Journal of Pharmaceutical Sciences 2011; 1(2): 194-
205. 
31. Dhake AS, Shinkar DM, Shayle S, Patil SB, Setty CM. Development and 
evaluation  of  mucoadhesive  tablets  of  clotrimazole  andits β­ cyclodextrin 
complex for the treatment of candidiasis. International Journal of Pharmacy 
and Pharmaceutical Sciences 2011; 3(3): 159­16. 
32. Chandiran IS, Narayanan V, Sushma S.  Formulation and evaluation of 
olanzapine as orodispersible drug delivery system by using beta cyclodextrin 
and  super  disintegrant.    International Journal of Pharmaceutical Sciences 
and Research 2011; 2(5): 1212-1216. 
33.  Yadav  VR,    Prasad  S,  Kannappan  R,    Ravindran  J,  Chaturvedi  MM,  
Vaahtera L,  Parkkinen J, et al. Cyclodextrin-complexed curcumin exhibits 
anti-inflammatory  and  antiproliferative  activities  superior  to  those  of 
curcumin through higher cellular uptake. Biochemical Pharmacology 2010; 
80:1021–1032. 
34.  Panda  M,  Ganesh  P,  Malpani  A,  Majji  S,  Rao  BME.  Effect  of  β-
cyclodextrin  on  physical  stability  of  nimesulide  suspension.  International 
Journal of Drug Development & Research 2010; 2(4): 669-675. 
35.  Vranic  E,  Uzunovic  A.  Dissolution  studies  of  physical  mixtures  of 
Indomethacin  with  alpha-  and  gamma-cyclodextrins.  Bosnian  Journal  of 
Basic Medical Science 2010; 10(3):197-203. 
36. Zhao YL, Wei H,  Zheng H,  Guo Z, Wei Y,  Zhang D, et al. Enhancing 
water-solubility of poorly soluble drug, asiatic acid with hydroxypropyl-β-
cyclodextrin. Digest Journal of Nanomaterials and Biostructures 2010; 5(2): 
419 – 425. 
37.  Jensen  CEM,  Santos  RAS,  Denadai  AML,  Santos  CFF,  Braga  ANG, 
Sinisterra  RD.  Pharmaceutical  Composition  of  Valsartan:  β-Cyclodextrin: 
Physico–Chemical  Characterization  and  Anti-Hypertensive  Evaluation. 
Molecules 2010; 15: 4067-4084. 
38.  Tirucherai  GS,  Mitra  AK.  Effect  of  hydroxypropyl  beta  cyclodextrin 
complexation on aqueous solubility, stability, and corneal permeation of acyl 
ester prodrugs of Ganciclovir. AAPS PharmSciTech 2003; 4(3): 1-12. 
39. Wang  S, Li D, Ito Y, Liu  X, Zhang J, Wu C.  An ocular  drug  delivery 
system  containing  zinc  diethyldithiocarbamate  and  HPβCD  inclusion 
complex--corneal permeability, anti-cataract effects and mechanism studies. 
J Pharm Pharmacol  2004; 56(10): 1251-7. 
40. Mohamed MAH, Mahmoud AA. Formulation of Indomethacin eye drops 
via  complexation  with  cyclodextrins.  Current  Eye  Research  2011;  36(3): 
208-216. 
41.  Rao  V,  Shyale  S.  Preparation  and  Evaluation  of  Ocular  Inserts 
Containing Norfloxacin. Turk J Med Sci 2004; 34:239-246. 
42.  Mahmoud  AA, El-Feky  GS, Kamel  R, Awad  GE. 
Chitosan/Sulfobutylether-β-cyclodextrin  nanoparticles  as  a  potential 
approach for ocular drug delivery. Int J Pharm    2011; 413(12): 229-36. 
43.  Abd  El-Bary  AA,  Salem  HF,  Kharshoum  RM.    2-Hydroxypropyl-ß-
Cyclodextrin Complex with Ketotifen Fumerate for Eye Drops Preparations. 
International Journal of Drug Delivery 2011; 3: 228-240. 
44. Cappello  B, Carmignani  C,  Iervolino  M,
  Rotonda  MIL,
  Saettone  MF. 
Solubilization  of tropicamide by  hydroxypropyl-β-cyclodextrin  and  water-
soluble  polymers:  in  vitro/in  vivo  studies.  International  Journal  of 
Pharmaceutics 2000; 213(1-2): 75-81. 
45. Jarvinen T, Jarvinen K, Urtti A, Thompson D, Stella VJ. Sulfobutyl Ether 
β-cyclodextrin  (SBE-β-CD)  in  eye  drops  improves  the  tolerability  of  a 
topically  applied  pilocarpine  prodrug  in  rabbits.  Journal  of  Ocular 
Pharmacology and Therapeutics 2009; 11(2): 95-106. 
46. Tirucherai GS,  Mitra  AK. Effect of Hydroxypropyl Beta Cyclodextrin 
complexation on aqueous solubility, stability, and corneal permeation of acyl 
ester prodrugs of Ganciclovir. AAPS PharmSciTech 2003; 4(3): 1-12. 
47. Mohamed MAH, Mahmoud AA. Formulation of Indomethacin eye drops 
via  complexation  with  cyclodextrins.  Current  Eye  Research  2011;  36(3): 
208-216. 
48.  Tanito  M,  Hara  K,  Takai  Y,  Matsuoka  Y,  Nishimura  N,  Jansook  P, 
LoftssonT,  Stefansson  E,  Ohira  A.  Topical  dexamethasone-cyclodextrin 
microparticle eye drops for diabetic macular edema.  IOVS 2011; 11-8178. 
49.  Ahad  HA,   Sreeramulu  J,   Padmaja  BS,   Reddy  MN,   Prakash  PG. 
Preparation of Fluconazole -Cyclodextrin Complex Ocuserts: In Vitro and In 
Vivo Evaluation. ISRN Pharmaceutics 2011; (2011): 1-8. 
50.  Loftsson T, Brewter ME. Cyclodextrin as Pharmaceutical  Excipients. 
Pharma Manager 1977; 5:22- 31.  
51. Jug M, Becirevic-Lacan M, Kwokal A, Cetina-Cizmek B. Influence of 
cyclodextrin  complexation  on  Piroxicam  gel  formulations.  Acta  Pharma 
2005; 56: 223-236. 
52.  Ammar  HO,  Salama  HA, Ghorab  M, El-Nahhas  SA, Elmotasem  H.  A 
Transdermal Delivery  System  for Glipizide. Current Drug Delivery 2006; 
3(3): 333-341. 
53. Roy SD, De GJ. Percutaneous absorption of nafarelin acetate, an LHRH 
analog, through human cadaver skin and monkey skin, Int. J. Pharm 1994; 
110: 137–145. 
54. Lakshmi PK, Kumar MK, Sridharan A, Bhaskaran S.  Formulation and 
evaluation  of  ibuprofen  topical  gel:  a  novel  approach  for  penetration 
enhancement.  International Journal of Applied Pharmaceutics. 2011; 3(3): 
25-30. Ali Nasir et al. IRJP 2012, 3 (4) 
Page 49 
55. Davaran D, Rashidi MR, Khandaghi R, Hashemi M. Development of a 
novel  prolonged-release  nicotine  transdermal  patch.  Pharmacological 
Research. 2005; 51(3): 233-237. 
56. Yang J, Wiley CJ, Godwin DA, Felton LA. Influence of hydroxypropyl-
beta-cyclodextrins  on      transdermal  penetration  and  photo  stability  of 
avobenzone.  European  Journal  of  Pharmaceutics  and  Biopharmaceutics. 
2007; 69(2): 605-612. 
57. Davaran S,  Hanaee J, Rashidi MR,  Valiolah F, Hashemi M. Influence of    
poly(ethylene  glycol)  α-cyclodextrin  complexes  on  stabilization  and 
transdermal  permeation  of  ascorbic  acid.  Journal  of  biomedical  materials 
research 2006; 78(3): 590–594. 
58. Rogayyeh S,   Mahvash K,   Tayebeh T,   Sadegh A,   Zohreh S,  Leila B. 
Enhancing  effect  of  cyclodextrins  on in  vitro skin  permeation  of  Hgh. 
Current Trends in Biotechnology and Pharmacy2010; 4(3). 
 59.  Panichpakdee J, Supapho P. Use of 2-hydroxypropyl-β-cyclodextrin as 
adjuvant  for  enhancing  encapsulation  and  release  characteristics  of 
asiaticoside within and from cellulose acetate ﬁlms. Elsevier. 2011; 85:251–
26. 
60.  Leng  W,  Qin  L,  Tang  X.  Chitosan  and  randomly  methylated  β-
cyclodextrin  combined  to  enhance  the  absorption  and  elevate  the 
bioavailability  of  estradiol  intranasally:  in  situ  and  in  vivo  studies.  The 
Journal of American Science 2006; 2(1): 61-65. 
61.  Grace  R,  Narayanan  N,  Ilavarasan  R.  Preparation  and  evaluation  of 
carbopol based nasal gels for systemic delivery of progesterone. International 
Journal of Pharmaceutical Research and Development 2010; 2(1). 
62. Jug M, Becirevic-Lacan M. Screening of mucoadhesive micro particles 
containing  hydroxypropyl-Beta-cyclodextrin  for  the  nasal  delivery  of 
risperidone. PubMed.2007; 10(5): 358-67. 
63.  Zhang X,  Zhang X, Wu Z, Gao X, Li C. β-cyclodextrin grafting hyper 
branched polyglycerols as carriers for nasal insulin delivery. Carbohydrate 
Polymers 2011; 84(4):1419-1425. 
64. Cho HJ, Balakrishnan  P, Park EK, Song  KW, Hong SS, Jang TY, Kim 
KS, Chung  SJ, Shim  CK, Kim  DD.  Poloxamer/cyclodextrin/chitosan-based 
thermoreversible gel for intranasal delivery of fexofenadine hydrochloride.  
Journal of Pharmaceutical Sciences 2011; 100(2):681-691. 
65. Mahajan HS, Shah SK, Surana SJ. Nasal in situ gel containing hydroxy 
propyl β-cyclodextrin inclusion complex of artemether: development and in 
vitro  evaluation.  Journal  of  Inclusion  Phenomena  and  Macrocyclic 
Chemistry 2011; 70(1-2): 49-58. 
66.  Cho  HJ,  Balakrishnan  P,  Shim  W,  Chung  S,  Shim  C,  Kim  D. 
Characterization  and  in  vitro  evaluation  of  freeze-dried  microparticles 
composed of granisetron–cyclodextrin complex and carboxymethylcellulose 
for  intranasal  delivery.  International  Journal  of  Pharmaceutics  2010;  400: 
59–65. 
67.  Bragagni M, Maestrelli F, Mennini N, Ghelardini C, Mura P. Liposomal 
formulations  of  prilocaine:  effect  of  complexation  with  hydroxypropyl-ß-
cyclodextrin on drug anesthetic efficacy. J Liposome Res 2010; 20(4): 315-
22. 
68. Dhule SS, Penfornis P, Frazier T, Walker R, Feldman J, Tan G, et al. 
Curcumin-loaded γ-cyclodextrin liposomal nanoparticles as delivery vehicles 
for  osteosarcoma.  Nanomedicine:  Nanotechnology,  Biology  and  Medicine 
2011. 
69.  Li  ChunLei,  Cui  J,  Wang  C,  Li  Y,  Zhang  L,  Xiu  X,  et  al.  Novel 
sulfobutyl  ether  cyclodextrin  gradient  leads  to  highly  active  liposomal 
irinotecan formulation. The Journal of Pharmacy and Pharmacology 2011; 
63(6): 765-773. 
70.    Maestrelli  F,  Gonzalez-Rodriguez  ML,  Rabasco  AM,  Ghelardini  C, 
Mura P. New “drug-in cyclodextrin-in deformable liposomes” formulations 
to  improve  the  therapeutic  efficacy  of  local  anaesthetics.  International 
Journal of Pharmaceutics 2010; 395(1-2): 222-231. 
71.  Singh  HP,  Tiwary  AK,  Jain  S.  Preparation  and  in  vitro,  in  vivo 
characterisation  of  elastic  liposomes  encapsulating  cyclodextrin-colchicine 
complexes for topical delivery of colchicine. Yakugaku Zasshi 2010; 130(3): 
397-407. 
72.  Motoyama  K,   Nakashima  Y, Aramaki  Y,   Hirayama  F,   Uekama  K,  
Arima  H.  In  Vitro Gene  Delivery  Mediated  by  Asialofetuin-Appended 
Cationic  Liposomes  Associated  with γ-Cyclodextrin  into  Hepatocytes. 
Journal of Drug Delivery 2010; 2011 (2011), 1-13. 
73.  Castellanos IJ, Flores G,  Griebenow K. Effect of cyclodextrins on α-
chymotrypsin  stability  and  loading  in  PLGA  microspheres  upon  S/O/W 
encapsulation. Journal of Pharmaceutical Sciences 2006; 95(4): 849-858. 
74. Kang F, Singh J.  Conformational stability of a model protein (bovine 
serum  albumin)  during  primary  emulsification  process  of  PLGA 
microspheres synthesis.  Int J Pharm 2003; 260: 149–156. 
75.  Zhang  WF,  Chen  XG,  Li  PW,  He QZ,  Zhou HY. Preparation and 
characterization  of  theophylline  loaded  chitosan/β-cyclodextrin 
microspheres.  Journal  of  Materials  Science:  Materials  In  Medicine  2008; 
19(1): 305-310. 
76.  Victor  SP,  Sharma  CP.  Development  and  evaluation  of  cyclodextrin 
complexed Hydroxyapatite nanoparticles for preferential albumin adsorption. 
Colloids Surf B Biointerfaces 2011; 85(2): 221-8. 
77. Azevedo MB, Tasic L, Fattori J, Rodrigues FH, Cantos FC, Ribeiro LP, 
et  al.  New  formulation  of  an  old  drug  in  hypertension  treatment:  the 
sustained release of Captopril from cyclodextrin nanoparticles. International 
Journal of Nanomedicine 2011; 2011(6): 1005 – 1016. 
78. Cai K, Li J, Luo Z, Hu Y, Hou Y, Ding X. β-Cyclodextrin conjugated 
magnetic nanoparticles for diazepam removal from blood. Chem. Commun 
2011; 47: 7719-7721. 
79.  Gavini  E, Spada  G,  Rassu G,  Cerri G,  Brundu A,  Cossu M,  et  al. 
Development of solid nanoparticles based on hydroxypropyl-β-cyclodextrin 
aimed for the colonic transmucosal delivery of diclofenac sodium. Journal of 
Pharmacy and Pharmacology 2011; 63(4): 472–482. 
80.  George  C,  Kuriakose  S,  George  S,  Mathew  T.  Antifungal  activity  of 
silver nanoparticle-encapsulated β-cyclodextrin against human opportunistic 
pathogens. Supramolecular Chemistry 2011; 23(8): 593-597. 
 
TABLE 1. PARAMETERS OF NATURAL CYCLODEXTRINS 
Parameters  α- CD  β-CD  γ-CD 
Empirical formula  C36H60O30  C42H70O35  C48H80O40 
Glucose residue  6  7  8 
Molecular mass  973  1135  1297 
Cavity diameter  0.47-0.53  0.6-0.66  0.75-0.83 
 
TABLE 2. EFFECT OF CDs IN ORAL DRUG DELIVERY 
Drug  Type of 
CDs 
Effect 
Diacerein
24  HP-β-CD  Enhanced stabilization 
against hydrolysis. 
Etoricoxib
25  HP-β-CD  Enhanced solubility and 
efficacy. 
Mefenamic acid, 
Niflumic acid  
Flufenamic acid
26 
HP-β-CD  Enhanced solubilisation of 
drug. 
Carvedilol
27  β-CD  Enhanced oral bioavailability 
of carvedilol. 
Siymarin
28  β-CD  Enhanced dissolution and 
sustained effect. 
Aceclofenac
29  β-CD  Enhanced dissolution and 
faster action. 
Felodipine 
30  β-CD  Enhanced dissolution. 
Clotrimazole
31  β-CD  Enhanced solubility and 
bioavailability. 
Olanzapine
32  β-CD  Enhanced dissolution and 
absorption. 
Curcumin
33  HP-γ-CD  Enhanced release and 
bioavailability. 
Nimesulide
34  β-CD  Enhanced physical stability. 
Indomethacin
35  α-CD, γ-
CD 
Enhanced solubility and 
dissolution. 
Asiatic Acid
36  HP-β-CD  Enhanced aqueous solubility 
of drug. 
Valsartan
37  β-CD  Enhanced solubility and 
efficacy. 
 
TABLE 3. EFFECT OF CDs IN OCULAR DRUG DELIVERY 
Drug  Type of 
CDs 
Effect 
Econazole nitrate
42  SBE-β-CD  Sustained release of drug. 
Ketotifen fumerate
43  2HP- β-CD  Enhanced solubility, stability, 
permeability. 
Tropicamide
44  HP-β-CD  Enhanced permeability and 
reduced irritation. 
Pilocarpine
45  SBE-β-CD  Improved tolerability of drug. 
Gancyclovir 
prodrugs
46 
HP- β-CD  Improved chemical and 
enzymatic stability. 
Indomethacin
47  HP-β-CD  Enhanced solubility, aqueous 
stability, permeation. 
Dexamethasone
48  CD  Enhanced tolerability. 
Fluconazole
49  β-CD  Enhanced solubility and 
penetration. 
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TABLE 4. EFFECT OF CDs IN TRANSDERMAL DRUG DELIVERY 
Drug  Type of CDs  Effect 
Ibuprofen
54  HP-β-CD  Enhanced transdermal permeation 
Nicotine
55  β-CD  Sustained release of drug. 
Avobenzone
56  HP-β-CD  Enhanced photo stability of drug. 
Ascorbic acid
57  α-CD  Enhanced stabilization and transdermal permeation. 
Human Growth Hormone
58  2HP-β-CD  Enhanced permeation across the skin. 
Asiaticoside
59  β-CD  Enhanced encapsulation and release features. 
 
TABLE 5. EFFECT OF CDs IN NASAL DRUG DELIVERY 
Drug  Type of CDs  Effect 
Fexofenadine HCl
64  HP-β-CD  Enhanced plasma concentration. 
Artemether
65  HP-β-CD  Enhanced drug release. 
Granisetron
66  HP-β-CD  Enhanced release profile of drug. 
 
TABLE 6. EFFECT OF CDs IN LIPOSOMAL DRUG DELIVERY 
Drug  Type of CDs  Effect 
Prilocaine
67  HPβCD  Enhanced anesthetic effect and duration. 
Curcumin
68  2HP-γ-CD  Enhanced efficiency. 
Irinotecan
69  SBECD  Prolonged release and protection against hydrolysis. 
Benzocaine ,Butamben
70  HPβCD  Enhancement of intensity and duration of anesthetic effect. 
Colchicine
71  βCD  Prolonged drug release and improved site specificity. 
Asialofetuin
72  γ-CD  Increased gene transfer activity. 
 
TABLE 7. EFFECT OF CDs IN MICROSPHERES DELIVERY 
Drug  Type of CDs  Effect 
α-chymotrypsin
73  M-β-CD  Enhanced stabilization of drug. 
Bovine Serum Albumin
74  HP-β-CD  Stabilization of protein. 
Theophylline
75  β-CD  Prolonged release of drug. 
 
TABLE 8. EFFECT OF CDs IN NANOPARTICLES DELIVERY 
Drug  Type of CDs  Effect 
Diazepam
78  β-CD  Effective as haemoadbsorbant for drug removal. 
Diclofenac Na
79  HP-β-CD  Effective colon-targeted delivery of drugs. 
Silver Acetate
80  β-CD  Enhanced efficacy of drug. 
 
 
 
 
Figure 1. OVERVIEW OF CYCLODEXTRIN MOLECULE GEOMETRY 
 